• Japanese
  • Korean
  • Chinese
Cover Image

Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Progressive Dementia with Other Neurological Abnormalities

Abstract

REPORT HIGHLIGHTS

The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.

The global sales of drugs to treat progressive dementia with other neurological abnormalities expected to reach $537.2 million in 2012 and $913.7 million by 2017, at a CAGR of 11.2% over the five-year forecast period.

Sales of drugs to treat Huntington's disease patients with progressive dementia and other neurological abnormalities expected to reach $354.4 million in 2012 and further increase to $566.8 million in 2017, at a CAGR of 9.8% over the five-year forecast period.

image1

REPORT SCOPE

INTRODUCTION

STUDY OBJECTIVES

BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global markets for treatments for syndromes of dementia and movement disorders. The key objective is to present a comprehensive analysis and the future direction of the market as it shapes drug and therapy development.

This report explores present and future strategies within the neurodegenerative disorder market, which includes treatments and therapies for progressive dementia, progressive dementia with other neurological abnormalities and movement disorders. Market gains, setbacks and needs are discussed in this report. Comparisons, usage and the advantages and disadvantages of different types of technologies, including small molecules and monoclonal antibodies, are also presented in this report.

A detailed analysis of the structure of the syndromes of dementia and movement disorder industry has been conducted. Revenues are broken down by neurodegenerative disease and primary clinical/pathological feature. Sales figures are estimated for the five-year period from 2012 through 2017.

Applications for syndromes of dementia and movement disorder treatments, or therapeutic technologies, are also discussed separately in the report, with an emphasis on small molecule and monoclonal antibodies technology. The report also covers significant patents and their allotment in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of syndromes of dementia and movement disorders and company collaborations with research institutes have highlighted the importance of understanding the nature of these disorders. New technological developments are providing disease-modifying therapies for the late stages of the disorders. Collaborations between research institutes and pharmaceutical companies are on the rise as state-of-the-art technology is being explored to develop more efficient products and therapies.

R&D spending, along with increasing competition, patent expiries and new technologies are taking the market in a new direction. Global market revenues increased from 2009 to 2011 and are expected to continue to show growth over the forecast period as new advances, launches and collaborations continue to influence the market. This study looks at most of the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type of technology in light of the new technologies, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This study contributes to the areas of market growth in treatments for Alzheimer's disease, Lewy body dementia, Pick's disease, Huntington's disease, corticobasal ganglionic degeneration, Parkinson's disease, multiple system atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses the neurodegenerative disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and Mexico.

METHODOLOGY

BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors' technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC spoke with officials within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this study is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Some of her other reports with BCC include Reagents for Chromatography; Spectroscopy - An Enduring Market; Advanced Drug Delivery Systems - Technologies and Global Markets; Orthopedic Drugs, Implants and Devices - Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry - The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging - Global Markets; Chiral Technology - Global Markets; Autacoids and Related Drugs - Technologies and Global Markets; Contraceptives - Technologies and Global Markets; Liver Disease Treatments - The Global Market; Hormone Replacement Therapies and Other Hormone Therapies - Global Markets; Cardiovascular Medicine - Diagnostics, Drugs and Devices; and Cancer Therapies - Technologies and Global Markets.

The lead consultant on this project is Ms. Ruma Chakravarty, who holds a master's degree in biophysics. She has tremendous experience in market research, quality, process improvement and lean and six sigma concepts.

Table of Contents

Chapter- 1: INTRODUCTION - Complimentary

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

Chapter- 2: EXECUTIVE SUMMARY

  • Table Summary : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017
  • Figure Summary : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017

Chapter- 3: OVERVIEW

  • THE BRAIN
  • CLASSIFICATION OF NEURODEGENERATIVE DISORDERS
  • NEURODEGENERATIVE DISORDERS
  • DIAGNOSTIC TESTS FOR NEURODEGENERATIVE DISORDERS

Chapter- 4: REGULATORY ASPECTS

  • INTRODUCTION
  • DRUG APPROVALS
  • REGULATORY DEVELOPMENTS AFFECTING SYNDROMES OF DEMENTIA AND MOVEMENT DISORDER PRODUCTS

Chapter- 5: NEW DEVELOPMENTS

  • Table 6 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2012
  • Table 7 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2011
  • Table 8 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010

Chapter- 6: GLOBAL MARKETS

  • MARKETS BY CLINICAL/PATHOLOGICAL FEATURE
  • MARKET BY DISEASE TYPE
  • MARKET BY REGION
  • MARKETS BY TECHNOLOGY

Chapter- 7: MARKET FOR DRUGS TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES

  • MARKET BY DISEASE TYPE
  • MARKET BY REGION
  • REGIONAL MARKETS BY DISEASE TYPE
  • MARKET BY TECHNOLOGY
  • INDUSTRY STRUCTURE

Chapter- 8: PATENT ANALYSIS

  • PATENTS ISSUED BY YEAR
  • PATENTS BY DISEASE CATEGORY
  • PATENTS BY DISEASE TYPE
  • PATENTS BY COUNTRY
  • PATENTS BY COMPANY

Chapter- 9: CURRENT SITUATION

  • MARKET TRENDS
  • OVERALL DRIVERS OF THE MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS
  • OTHER FACTORS AFFECTING THE MARKET
  • COLLABORATIONS/MERGERS AND ACQUISITIONS

Chapter- 10: COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ABLYNX NV
  • ACCERA INC.
  • ACORDA THERAPEUTICS INC.
  • ACTAVIS ELIZABETH
  • AFFIRIS AG
  • ALLIANCE PHARMA PLC
  • ALLON THERAPEUTICS INC.
  • ALPHAPHARM
  • ALZHYME LTD.
  • AMERICAN REGENT INC.
  • APOTEX INC.
  • APOTHECA INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA GMBH
  • AUROBINDO PHARMA LTD.
  • BAXTER INTERNATIONAL INC.
  • BELLUS HEALTH INC.
  • BOEHRINGER INGELHEIM LTD.
  • BRISTOL-MYERS SQUIBB
  • BRYANT RANCH PREPACK
  • CADILA HEALTHCARE LTD.
  • CARACO PHARMACEUTICAL LABORATORIES
  • CARDINAL HEALTH
  • CELLZOME AG
  • CIPLA LTD.
  • COGNITION THERAPEUTICS INC.
  • COLUCID PHARMACEUTICALS INC.
  • COMENTIS INC.
  • CORTEX PHARMACEUTICALS
  • CYTOS BIOTECHNOLOGY AG
  • DAIICHI SANKYO CO. LTD.
  • DR. REDDY'S LABORATORIES LTD.
  • EISAI CO. LTD.
  • ELAN PHARMA INTERNATIONAL LTD.
  • ELI LILLY AND CO.
  • ENDO PHARMACEUTICALS INC.
  • ENVIVO PHARMACEUTICALS
  • EVOTEC AG
  • EPITOMICS INC.
  • EXONHIT THERAPEUTICS SA
  • FOREST LABORATORIES INC.
  • GLAXOSMITHKLINE PLC
  • GLENMARK GENERICS LTD.
  • H. LUNDBECK A/S
  • HAMELN PHARMACEUTICALS LTD.
  • HELICON THERAPEUTICS INC.
  • HOSPIRA INC.
  • INTELLECT NEUROSCIENCES INC.
  • INTRA-CELLULAR THERAPIES INC.
  • JAZZ PHARMACEUTICALS PLC
  • MAJOR PHARMACEUTICALS
  • MEDIVATION INC.
  • MEMORY PHARMACEUTICALS CORP.
  • MERCK SERONO
  • MERCK SHARP & DOHME LTD.
  • MERZ PHARMA GMBH & CO KGAA
  • MITHRIDION INC.
  • MYLAN PHARMACEUTICALS
  • NEUREN PHARMACEUTICALS LTD.
  • NEURO-HITECH INC.
  • NEUROPTIX CORP.
  • NEUROSEARCH A/S
  • NEWRON PHARMACEUTICALS SPA
  • NOSCIRA SA
  • NOVARTIS AG
  • NYMOX PHARMACEUTICAL CORP.
  • ORCHID CHEMICALS & PHARMACEUTICALS LTD.
  • ORION CORP.
  • ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC.
  • PAR PHARMACEUTICALS
  • PERRIGO CO.
  • PFIZER INC.
  • PHARNEXT
  • PHYSICIANS TOTAL CARE INC.
  • PLIVA HRVATSKA D.O.O.
  • PRASCO LABORATORIES
  • RANBAXY LABORATORIES LTD.
  • ROCHE HOLDING LTD.
  • ROXANE LABORATORIES INC.
  • SANDOZ INTERNATIONAL GMBH
  • SANOFI
  • SANTHERA PHARMACEUTICALS
  • SHIONOGI & CO.
  • STADA ARZNEIMITTEL AG
  • SUN PHARMA
  • TAJ PHARMACEUTICALS LTD.
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • TERCICA INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • TORRENT PHARMA
  • UCB SA
  • UDL LABORATORIES
  • UPSHER-SMITH LABORATORIES
  • VALEANT PHARMACEUTICALS
  • VERNALIS PLC
  • WATSON PHARMACEUTICALS INC.
  • WEST-WARD PHARMACEUTICAL

Chapter- 11: APPENDIX I: ABBREVIATIONS

List of Tables

  • Summary Table : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017
  • Table 1 : CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY PRIMARY CLINICAL/PATHOLOGICAL FEATURE
  • Table 2 : ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012
  • Table 3 : PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS
  • Table 4 : FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012
  • Table 5 : FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012
  • Table 6 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2012
  • Table 7 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2011
  • Table 8 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010
  • Table 9 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017
  • Table 10 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011
  • Table 11 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR NEURODEGENERATIVE DISORDERS, THROUGH 2017
  • Table 12 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011
  • Table 13 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, THROUGH 2017
  • Table 14 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011
  • Table 15 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017
  • Table 16 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011
  • Table 17 : CHDI FOUNDATIONS' KEY DEVELOPMENTS IN TREATING HUNTINGTON'S DISEASE
  • Table 18 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, THROUGH 2017
  • Table 19 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011
  • Table 20 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, THROUGH 2017
  • Table 21 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011
  • Table 22 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON'S DISEASE BY REGION, THROUGH 2017
  • Table 23 : GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION BY REGION, THROUGH 2017
  • Table 24 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, THROUGH 2017
  • Table 25 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011
  • Table 26 : LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HUNTINGTON'S DISEASE
  • Table 27 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON'S DISEASE, 2011
  • Table 28 : LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HUNTINGTON'S DISEASE
  • Table 29 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011
  • Table 30 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012
  • Table 31 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012
  • Table 32 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012
  • Table 33 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-MARCH 2012
  • Table 34 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
  • Table 35 : U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIA BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
  • Table 36 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
  • Table 37 : U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
  • Table 38 : NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012
  • Table 39 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY COMPANY, 2010-MARCH 2012

List of Figures

  • Summary Figure : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017
  • Figure 1 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017
  • Figure 2 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011
  • Figure 3 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR NEURODEGENERATIVE DISORDERS, 2010-2017
  • Figure 4 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011
  • Figure 5 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2010-2017
  • Figure 6 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011
  • Figure 7 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017
  • Figure 8 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011
  • Figure 9 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, 2010-2017
  • Figure 10 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011
  • Figure 11 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2010-2017
  • Figure 12 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011
  • Figure 13 : GLOBAL SALES OF DRUGS USED TO TREAT HUNTINGTON'S DISEASE BY REGION, 2010-2017
  • Figure 14 : GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION BY REGION, THROUGH 2017
  • Figure 15 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2010-2017
  • Figure 16 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011
  • Figure 17 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS FOR USED TO TREAT HUNTINGTON'S DISEASE, 2011
  • Figure 18 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011
  • Figure 19 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010 - MARCH 2012
  • Figure 20 : PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012
  • Figure 21 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012
  • Figure 22 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012*
  • Figure 23 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-MARCH 2012
  • Figure 24 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
  • Figure 25 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
Show More
Pricing
Get Notified
Email me when related reports are published